AstraZeneca ((AZN)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), Daiichi Sankyo Company ((DSKYF)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
AstraZeneca and Daiichi Sankyo are conducting a Phase 1b study, titled ‘DESTINY-Breast08’, to evaluate the safety and effectiveness of Trastuzumab Deruxtecan (T-DXd) in combination with other cancer treatments for patients with metastatic HER2-low breast cancer. The study aims to find optimal dosing and assess anti-tumor activity, which is crucial for developing new treatment options for this patient group.
The study is testing various combinations of T-DXd with other drugs such as Capecitabine, Durvalumab, Paclitaxel, Capivasertib, Anastrozole, and Fulvestrant. These combinations are designed to enhance treatment efficacy and provide new therapeutic avenues for patients.
This interventional study is non-randomized with a parallel assignment model, and it is open-label, meaning both researchers and participants know which treatments are being administered. The primary goal is treatment-focused, aiming to improve patient outcomes.
The study began on December 17, 2020, and while it is not currently recruiting, it remains active. The latest update was submitted on July 31, 2025, indicating ongoing progress and adjustments.
The outcome of this study could significantly impact AstraZeneca and Daiichi Sankyo’s market positions by potentially introducing a new, effective treatment for breast cancer. This could positively influence stock performance and investor sentiment, especially if the results show significant clinical benefits over existing treatments.
The study is ongoing, and further details can be found on the ClinicalTrials portal.